Vektor Medical, a leader in non-invasive arrhythmia analysis and localization, today announced new data demonstrating the enhanced capabilities of its AI-powered solution, vMap, for improving cardiac arrhythmia treatment. The data, to be presented at the American Heart Association (AHA) Scientific Sessions 2024 on November 17, shows that vMap achieved an impressive 91.1% accuracy in distinguishing epicardial from endocardial ventricular tachycardia. This marks a significant improvement over traditional visual ECG analysis, which only achieved 62.5% accuracy.
As the only FDA-cleared, non-invasive, AI-based arrhythmia mapping tool, vMap empowers cardiologists to precisely localize arrhythmia sources with a standard 12-lead ECG. This enables a more efficient and effective approach to treating arrhythmias.
Study Details and Results
In the study, researchers analyzed 136 episodes of arrhythmia or pacing from 72 patients, evenly split between epicardial and endocardial sources. The vMap algorithm demonstrated a 91.1% accuracy rate, along with a high sensitivity of 97.1%, far surpassing the performance of traditional visual ECG methods.
“vMap represents a significant advancement in arrhythmia care,” said Dr. Venkat Tholakanahalli, Chief of Electrophysiology at the Minneapolis VA Health Care System. “With its ability to accurately pinpoint arrhythmia sources, vMap helps us tackle complex cases more effectively, leading to better patient outcomes. As arrhythmia prevalence rises, tools like vMap are invaluable in streamlining procedures, optimizing our clinical workflow, and enhancing procedural efficiency. This data highlights the transformative role of AI in cardiac care and the impact of Vektor Medical’s innovation on clinical practice.”
Presentation Details
The study will be presented on Sunday, November 17, at 11:30 a.m. at the American Heart Association Scientific Sessions 2024 in Chicago.
About vMap®
vMap is the only FDA-cleared, non-invasive AI-based tool for mapping arrhythmias using a standard 12-lead ECG. It accurately localizes arrhythmia sources for various types, including focal arrhythmias and atrial fibrillation, as well as ventricular tachycardia. By extracting actionable insights from the ECG, vMap allows physicians to quickly and precisely identify the source of arrhythmias, improving patient outcomes and reducing procedure time. Clinical evidence continues to support vMap’s potential to optimize workflow across the entire arrhythmia care pathway.
About Vektor Medical
Headquartered in San Diego, Vektor Medical is committed to revolutionizing arrhythmia care with its AI-powered, non-invasive technology. Through its flagship solution, vMap, the company aims to improve the outcomes of cardiac ablation procedures, increase procedural efficiency, and streamline clinical workflows, ultimately enhancing the quality of care for millions of patients affected by atrial fibrillation and other arrhythmias.
